Follow Us

Law.com Subscribers SAVE 30%

Call 855-808-4530 or email GroupSales@alm.com to receive your discount on a new subscription.

Corporate Governance General Counsel and In House Counsel Information Governance and Compliance Regulations Trade Secrets

Preventing Insider Trading at Biopharma Companies

Biopharma companies and their insiders often possess material, nonpublic information. And since company equity usually makes up a large part of insiders' compensation, legal issues arise when they have access to such information and want to trade their equity.

X

Thank you for sharing!

Your article was successfully shared with the contacts you provided.

Between clinical trial results, open-label trials, licensing and collaboration discussions, and acquisition or sale talks, development and clinical-stage public biopharma companies and their insiders often possess material, nonpublic information. And since company equity usually makes up a large part of insiders’ compensation, legal issues arise when insiders have access to such information and want to trade their equity. To complicate matters, market regulators are watching and will be quick to ask who knew what, when they knew it, and who traded whenever a company’s stock price moves significantly. To protect against insider trading risks and regulatory scrutiny, it is key to have a robust control environment for insider trading.

Read These Next